Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Winer

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Advances in Therapy|April 22, 2025
Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone DeficiencyAndrew R Hoffman, Subhara Raveendran, Janna Manjelievskaia, et al.
Open Forum Infectious Diseases|December 18, 2024
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United StatesHagit Kopel, Andre B Araujo, Alina Bogdanov, et al.
Vaccines|October 26, 2024
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United StatesHagit Kopel, Van Hung Nguyen, Alina Bogdanov, et al.
Vaccines|November 25, 2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in AdultsHagit Kopel, Van Hung Nguyen, Catherine Boileau, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Advances in Therapy|April 22, 2025
Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone DeficiencyAndrew R Hoffman, Subhara Raveendran, Janna Manjelievskaia, et al.
Open Forum Infectious Diseases|December 18, 2024
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 Vaccine (mRNA-1273.815) in Preventing COVID-19-related Hospitalizations and Medical Encounters Among Adults in the United StatesHagit Kopel, Andre B Araujo, Alina Bogdanov, et al.
Vaccines|October 26, 2024
Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United StatesHagit Kopel, Van Hung Nguyen, Alina Bogdanov, et al.
Vaccines|November 25, 2023
Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in AdultsHagit Kopel, Van Hung Nguyen, Catherine Boileau, et al.
Pageof 2